Luzhu Biotechnology

Beijing Luzhu Biotechnology Co., Ltd (HKG: 2480), a leading manufacturer of human vaccines and therapeutic biologics, has declared the successful completion of patient enrollment for the Phase III clinical study of its vaccine candidate LZ901 in China. Over 98% of the participants have received the requisite two doses of either…